Published in Physiol Rev on July 01, 2003
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron (2006) 4.12
Neural syntax: cell assemblies, synapsembles, and readers. Neuron (2010) 3.75
Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci (2006) 3.00
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A (2005) 2.96
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Cannabis and psychosis. BMJ (2006) 2.44
Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol (2009) 2.35
Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron (2013) 2.18
Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol (2007) 2.08
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Endocannabinoid signaling and synaptic function. Neuron (2012) 1.90
Coactivation of pre- and postsynaptic signaling mechanisms determines cell-specific spike-timing-dependent plasticity. Neuron (2007) 1.86
Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. Neuron (2007) 1.85
Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron (2007) 1.81
Supply and demand for endocannabinoids. Trends Neurosci (2011) 1.78
Activity-dependent regulation of synapses by retrograde messengers. Neuron (2009) 1.73
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One (2007) 1.67
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Persistently active cannabinoid receptors mute a subpopulation of hippocampal interneurons. Proc Natl Acad Sci U S A (2004) 1.64
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning. Hippocampus (2015) 1.63
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron (2005) 1.58
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling. Cell (2015) 1.49
Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A (2010) 1.49
Synaptic cross talk between perisomatic-targeting interneuron classes expressing cholecystokinin and parvalbumin in hippocampus. J Neurosci (2009) 1.47
Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology (2009) 1.47
Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology (2010) 1.46
Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.44
Long-term plasticity at inhibitory synapses. Curr Opin Neurobiol (2011) 1.41
Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci (2011) 1.37
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol (2004) 1.35
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A (2005) 1.33
Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci (2010) 1.32
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol (2004) 1.30
E-I balance and human diseases - from molecules to networking. Front Mol Neurosci (2008) 1.29
Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol (2004) 1.29
Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. Neuropsychopharmacology (2010) 1.29
Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity. J Physiol (2010) 1.27
Interneuron activity controls endocannabinoid-mediated presynaptic plasticity through calcineurin. Proc Natl Acad Sci U S A (2008) 1.27
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol (2005) 1.26
Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des (2008) 1.26
Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci (2010) 1.26
Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci (2008) 1.25
PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol (2006) 1.25
Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem (2007) 1.24
Cortical basket cell dysfunction in schizophrenia. J Physiol (2012) 1.22
Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci U S A (2005) 1.21
Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol (2003) 1.20
The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci (2005) 1.20
Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl) (2007) 1.20
Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol (2004) 1.20
Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. Schizophr Bull (2011) 1.20
Molecular signals of plasticity at the tetrapartite synapse. Curr Opin Neurobiol (2011) 1.20
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. Psychopharmacology (Berl) (2009) 1.19
Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurones in juvenile mouse neocortex. J Physiol (2004) 1.19
Retrograde endocannabinoid signaling in a postsynaptic neuron/synaptic bouton preparation from basolateral amygdala. J Neurosci (2005) 1.19
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem (2008) 1.18
Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience (2011) 1.18
Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex (2009) 1.17
Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem (2008) 1.15
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci U S A (2006) 1.15
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology (2010) 1.14
Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry (2012) 1.14
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) (2011) 1.14
Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) (2008) 1.13
Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron (2012) 1.13
Metaplastic control of the endocannabinoid system at inhibitory synapses in hippocampus. Proc Natl Acad Sci U S A (2008) 1.13
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol (2007) 1.12
Cannabinoid sensitivity and synaptic properties of 2 GABAergic networks in the neocortex. Cereb Cortex (2008) 1.12
Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br J Pharmacol (2010) 1.11
Glutamatergic transmission and plasticity between olfactory bulb mitral cells. J Physiol (2008) 1.11
Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience (2010) 1.10
Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system. Childs Nerv Syst (2016) 1.08
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci (2007) 1.08
Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol (2013) 1.08
Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci (2008) 1.08
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res (2009) 1.07
Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol (2010) 1.07
Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res (2007) 1.07
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 1.05
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol (2006) 1.05
Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol (2006) 1.04
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci (2010) 2.73
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci (2007) 2.32
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
A novel network of multipolar bursting interneurons generates theta frequency oscillations in neocortex. Neuron (2003) 2.05
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab (2010) 1.91
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain (2009) 1.70
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol (2007) 1.63
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology (2005) 1.49
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett (2008) 1.36
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology (2003) 1.30
Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A (2011) 1.29
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A (2009) 1.25
Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. Cell Metab (2011) 1.25
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun (2012) 1.24
Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. Proc Natl Acad Sci U S A (2011) 1.23
Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol (2007) 1.22
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol (2009) 1.20
Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J Lipid Res (2007) 1.20
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther (2007) 1.18
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol (2008) 1.16
Conduction block in PMP22 deficiency. J Neurosci (2010) 1.16
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol (2009) 1.14
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids (2002) 1.11
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem (2009) 1.11
Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci (2012) 1.10
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab (2012) 1.09
Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). Am J Physiol Regul Integr Comp Physiol (2005) 1.09
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci (2012) 1.08
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Targeted lipidomics: signaling lipids and drugs of abuse. Prostaglandins Other Lipid Mediat (2005) 1.07
Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol (2011) 1.07
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur J Neurosci (2004) 1.06
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res (2012) 1.06
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke (2002) 1.04
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci (2010) 1.04
Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann Chim (2007) 1.04
Rapid pain modulation with nuclear receptor ligands. Brain Res Rev (2008) 1.03
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep (2013) 1.02
Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology (2005) 1.02
Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem (2006) 1.01
Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol (2009) 1.01
Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) (2008) 1.01
Regulation of brain anandamide by acute administration of ethanol. Biochem J (2007) 0.99
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain (2012) 0.99
The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci (2007) 0.98
New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations. PLoS One (2013) 0.98
Brown adipose tissue quantification in human neonates using water-fat separated MRI. PLoS One (2013) 0.97
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem (2008) 0.97
Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem (2010) 0.97
Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep (2003) 0.96
Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol (2006) 0.96
Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) (2007) 0.95
Conformational effects in enzyme catalysis: reaction via a high energy conformation in fatty acid amide hydrolase. Biophys J (2006) 0.94
Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res (2004) 0.94
Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods Mol Biol (2009) 0.93
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) (2006) 0.93
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem (2009) 0.93
Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci (2012) 0.93